RELPAX

Superior pain relief vs Imitrex® (sumatriptan succinate) 100 mg
In 2 clinical trials, more people taking RELPAX 40 mg experienced migraine pain relief at both 2 and 24 hours compared with those taking Imitrex 100-mg tablets.1,2*
See full study descriptions below.
*Pain relief was measured in terms of headache response, defined as a reduction from severe or moderate headache to mild headache or no pain after medication.
See full study descriptions
Want relief for your patients’ migraines and their wallets?
With the RELPAX $4 Savings Card, eligible patients may pay as little as $4 for RELPAX, for a 30-day supply per month.†
†Some exclusions apply. See full Terms and Conditions at RELPAX.com/savings-terms.
Savings Offer will be accepted only at participating pharmacies. Savings Offer is not health insurance. No membership fees. Maximum savings $150 per month for 12 uses. This offer is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare or other federal or state healthcare programs. This offer is not valid for prescriptions that are eligible to be reimbursed in whole by private insurance plans or other health or pharmacy benefit programs. For help with the RELPAX $4 Savings Offer, call 1-800-926-5334, visit RELPAX.com, or write: Pfizer, ATTN: RELPAX, PO Box 4937, Warren, NJ 07059.
Help patients save on brand-name RELPAX
Preparing patients with RELPAX
  • Encourage patients to carry two 40-mg tablets of RELPAX:
  • 1st 40-mg tablet, with or without food, when migraine presents
  • 2nd 40-mg tablet if migraine improves but comes back after 2 hours
  • Do not exceed 2 RELPAX 40-mg tablets within 24 hours
Get complete dosing information
There is only one brand-name RELPAX
Help ensure your patients receive their RELPAX by writing “No Substitutions,” “Dispense As Written (DAW),” or “Brand Medically Necessary,” depending on your state’s requirements.
Help patients save on brand-name RELPAX
Study Descriptions
 
Adapted from Sandrini et al, Neurology, 2002.
Results from a multicenter, randomized, double-blind, placebo-controlled, parallel-group study of eletriptan (40 mg) and oral sumatriptan (50, 100 mg) in patients (N=774) with moderate to severe migraine headache. Headache response was defined as an improvement from headache severity grade 2 to 3 at baseline to grade 0 or 1 postdose. Headache response rates at 1 and 2 hours, respectively, were 12%, and 31% for placebo; 24%, and 50% for sumatriptan 50 mg: 27% and 53% for sumatriptan 100 mg; and 30% and 64% for eletriptan 40 mg. All doses of eletriptan were superior to sumatriptan at 2 hours for headache response and complete pain relief (P<.05). Sustained headache response at 24 hours was 50% for eletriptan 40 mg, 34% for sumatriptan 50 mg, 38% for sumatriptan 100 mg, and 21% for placebo; statistical comparisons between eletriptan vs placebo and both doses of sumatriptan were significantly different (P<.05). Eletriptan and sumatriptan were well tolerated.
 
Adapted from Mathew et al, Headache, 2003.
Results from a multicenter, randomized, double-blind, placebo-controlled, parallel-group study of oral eletriptan 40 mg and oral sumatriptan 100 mg in patients (N=2113) with moderate to severe migraine headache. Headache response was defined as reduction from a severe or moderate headache to a mild headache or no pain postdose. Secondary endpoints included headache response rates at 1 hour, pain-free rates, absence of associated symptoms, functional response at 1 and 2 hours, and sustained headache response. Headache response rates at 2 hours postdose were significantly higher for eletriptan 40 mg (67%) than for sumatriptan 100 mg (59%; P<.001) and placebo (26%; P<.0001). Sustained headache response at 24 hours was 43% for eletriptan 40 mg, 34% for sumatriptan 100 mg, and 14% for placebo; differences vs placebo were statistically significant (P<.0001). Eletriptan 40 mg consistently showed significant (P<.01) efficacy over sumatriptan 100 mg across secondary clinical outcomes. Both eletriptan and sumatriptan were well tolerated and most adverse events were mild and transient.